The National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation.
The National Institute for Health and Care Excellence

NICE Listens: hearing the public’s views on AI in health and care

That is why AI is the right next topic for NICE Listens. The dialogue will explore how people want AI to be used in health ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...
National Institute for Health and Care Excellence

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma

There is a simple discount patient access scheme for glofitamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)

NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.
National Institute for Health and Care Excellence

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over

Evidence-based recommendations on 12 standardised quality betula verrucosa pollen sublingual lyophilisate (12 SQ-Bet SLIT; Itulazax) for treating moderate to severe allergic rhinitis or conjunctivitis ...
National Institute for Health and Care Excellence

Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence

There is a simple discount patient access scheme for ribociclib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

There is a simple discount patient access scheme for brentuximab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal)

NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.